If dose will be change to 700 mg , all then will count as
If dose will be change to 700 mg , all then will count as 700 mg , and at the end after one year results should not be " tainted"..imo.
Patients will be for a long time on 700 mg.
But results will not be as good as they should , because for entire year patients developing high PD-L1 will not be given check point inhibitors..
If dose will not be change and some will be on 350 mg , they can "taint" our results of course , but statistics will show % of results in each dose.
I am only worry if they will switch all to 700 mg.
They will have a second DSMB when 20 patients will be for at least 21days on LL.
If enrollment very fast , most will be about 3 weeks on treatment and it may not be enough to see the difference between the doses , as we know for PD-L1 to become elevated it takes 30-90 days on LL.
The only thing is , most probably enrollment will not be that fast , and the 700 mg patients will start to show some improvements with cancer , and elevation of PD-L1 by the time of second DSMB evaluation..
I just still don't know how they will evaluate cancer progression as there is nothing about doing MRI time to time in the protocol..
If anyone is willing , this is a good Q to our company/Dr Jay. How you will evaluate progress with cancer for this year.
Will MRI be done ??.
Normally those things are written in the protocol.
All IMO.
22
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Investors Take Aim at Everest Group's Alleged Missteps Looks like Everest Group, Ltd. (NYSE: EG) has found itself knee-deep in legal quicksand. There's a class-action lawsuit afoot, spearheaded by the folks at Schall, Brown & Schwartz LLP. They're putting forward claims that Everest, a player in the securities exchange, was painting a misleading picture when it came to...
Continue Reading
Doppel Boosts Its Team with PropRise Founders The market doesn’t lie: when a company's on a roll, you watch it closely. Doppel's latest move is a serious signal. They've snagged PropRise, a sprightly Y Combinator graduate, and landed its founders, Jean-Michael Diei and Matthew Krager, right into their engineering fold. These guys aren't greenhorns—cutting their teeth...
Continue Reading
Sausage Politics: A Tasty New Agenda Well, ain't that something? A sausage campaign running parallel to the midterms wasn't exactly on my bingo card. But here we are, America, dealing with a 'Sausage Tsunami.' This cheeky strategy from Johnsonville sure packs a punch, leveraging electoral fatigue to put sausage right where they want it: on your dinner plate. The Campaign...
Continue Reading
Budget Pains for Silvercorp's El Domo Project Folks, if you thought navigating the stock market was a minefield, try mining these days. Silvercorp Metals Inc. had to bump up its budget for the El Domo project in Ecuador—again. This time by $14.6 million. What's causing this fiscal heartache? Everything from rising diesel prices thanks to Ecuador playing games with...
Continue Reading
The Winds of Change Are Blowing Through Washington It looks like the face of Congress is getting a combat-ready makeover with the latest election results. Veterans are stepping up to the plate, claiming at least 79 seats in the 120th Congress, with a historic presence of women veterans making waves. Yeah, we're talking about 11 women veterans hitting the halls of power,...
Continue Reading
Unearthing the Hidden Struggle of PAH The American Lung Association (ALA) is getting loud about a quiet killer—pulmonary arterial hypertension (PAH) is in their spotlight this month, and it's about time. Documenting the horror stories of some 500 to 1,000 new PAH diagnoses each year in the U.S., the ALA is peeling back the blinds on a condition that's too often...
Continue Reading
No one just stumbles into 400 successful deals without a whole lot of grit, especially in the gnarly jungle of health care services mergers and acquisitions. The Braff Group, a stalwart in this arena since 1998, has just hit this remarkable milestone. If you ask me, this isn't just a number—it's a testament to the blood, sweat, and relentless dedication poured into...
Continue Reading
A Closer Look at LYMPHIR's Impact on CTCL Patients Well, here's a whiff of genuine hope for folks grappling with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Coming out of New Jersey, Citius Oncology has dished out some pretty promising news, fresh from the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group's annual...
Continue Reading
A Legal Storm Brewing It's like walking into a saloon, expecting a smooth drink, only to find a bar fight breaking out in front of you. That's the scene with Webull Corporation (NASDAQ: BULL) right now. This time, they ain't just shooting the breeze; they're in the line of legal fire. SBS Law, a heavyweight in shareholder rights, is rallying the troops for a class action...
Continue Reading
Rolling With NACCO's Financial Punches Well, folks, when it rains, it pours—numbers that is. NACCO Industries just laid out their Q3 results for all to gawk at, and it's a mixed bag of triumphs and tussles. You got a gross profit of $11.8 million, a sweet 18% jump on the same quarter last year. Now, you're talking about revenue muscle, and there it is. Income before...
Continue Reading
Top 5 Most Recently Viewed Articles
Visa Inc Reports Strong Financial Growth Visa Inc (NYSE: V) has recently shared its fiscal fourth quarter and full year 2024 earnings, demonstrating a robust financial performance characterized by substantial increases in net revenue and earnings per share (EPS). Notably, the company reported an impressive 8% growth in overall payments volume and a 13% increase in...
Continue Reading
Jackson State University Receives Grant for Cybersecurity Lab Jackson State University (JSU) is set to enhance its academic offerings with the introduction of a Critical Power Grid Network Security Lab, thanks to a generous $2 million grant from the Entergy Charitable Foundation. This partnership marks a significant milestone for JSU as it reinforces its commitment to...
Continue Reading
Novartis Partners with NFL for Health and Wellness Initiatives In an exciting collaboration, Novartis, a prominent leader in innovative medicines, has joined forces with the National Football League (NFL) as the first-ever corporate pharmaceutical partner. This groundbreaking agreement is set to leverage the fervent passion of football fans to encourage a commitment to...
Continue Reading
S&P 500 Closes Lower, Ending Strong First Half of 2024 At 5,460.48, the S&P 500 ended Friday down 0.41%. Though the index fell, it had a great first half of 2024, rising 14.5%. Investors were pleased to see slowing inflation in the economic data released on Friday. Before retreating, the index had earlier in the session hit a new intraday high. Equally falling, the Nasdaq...
Continue Reading
Copper Sky Design + Remodel: A Celebration of Creativity In a remarkable achievement, Copper Sky Design + Remodel has garnered acclaim as HGTV's Overall Winner in the prestigious "Designer of the Year" competition. This talented Atlanta-based renovation firm has once again demonstrated its outstanding skill in creating beautiful and functional spaces. Judging Panel and...
Continue Reading